Stewart Alistair Balfour Richard's Insider Trades & SAST Disclosures
Stewart Alistair Balfour Richard's most recent trade in Achieve Life Sciences Inc. was a trade of 10,000 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stewart Alistair Balfour Richard.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Chieve Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 17 Mar 2025 | 10,000 | 60,876 (0%) | 0% | 2.9 | 28,598 | Common Stock |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Chieve Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 157,500 | 157,500 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Chieve Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 22,500 | 0 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 22,500 | 61,001 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.51 per share. | 19 Apr 2024 | 10,125 | 50,876 (0%) | 0% | 4.5 | 45,664 | Common Stock |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Mar 2024 | 10,000 | 10,000 | - | - | Common Stock Warrants (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 04 Mar 2024 | 10,000 | 38,501 (0%) | 0% | 4.6 | 45,850 | Common Stock |
| Achieve Life Sciences Inc. | Richard Stewart Alistair Balfour | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 140,000 | 140,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Stewart Alistair Balfour Richard | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 5,000 | 0 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 5,000 | 30,751 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.29 per share. | 28 Apr 2023 | 2,250 | 28,501 (0%) | 0% | 8.3 | 18,653 | Common Stock |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2023 | 22,500 | 22,500 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2023 | 22,500 | 35,876 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.80 per share. | 21 Apr 2023 | 10,125 | 25,751 (0%) | 0% | 6.8 | 68,850 | Common Stock |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 75,000 | 75,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 5,000 | 15,626 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 5,000 | 5,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.43 per share. | 28 Apr 2022 | 2,250 | 13,376 (0%) | 0% | 7.4 | 16,718 | Common Stock |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 45,000 | 45,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc. | Richard Alistair Balfour Stewart | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 10,000 | 10,000 | - | - | Performance Restricted Stock Unit (PRSU) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges